Efficacy of Intravenous Glyco-P® in Patients Undergoing Procedure That Require Anesthesia Service
This observational study was designed to prove clinical efficacy of the well known "glycopyrrolate" which is considered an orphan drug in Thailand. Since the medication has never been officially used in Thai people and this particular brand "Glyco-P" which was made in India has never been officially proven of its efficacy in Thai people. The study was aimed to prove if this Glyco-P can modestly increase patient's heart rate, decrease secretion and safely used in combination with neostigmine for reversal of non-depo muscle relaxant drugs.
Prevention of Drooling
Reversal of Muscle Relaxants
|Study Design:||Time Perspective: Prospective|
|Official Title:||Efficacy of Intravenous Glyco-P® in Patients Undergoing Procedure That Require Anesthesia Service|
- Efficacy of Glyco-P as an antisialagogue [ Time Frame: 3 months ] [ Designated as safety issue: No ]Examine efficacy of Glyco-P for reduction of secretion and also for prevention of secretion. The secretions score ranges from 0-5 was evaluated by a person who was blinded to treatment before and after treatment.
|Study Start Date:||July 2012|
|Study Completion Date:||April 2013|
|Primary Completion Date:||March 2013 (Final data collection date for primary outcome measure)|
A group of patients enrolled to prove efficacy of Glyco-P for reduction of secretions.
A group of patients enrolled to prove efficacy of Glyco-P for modest increase of heart rate.
For reversal of neuromuscular blocking agents
Group of patients enrolled to prove efficacy of Glyco-P when used in combination with neostigmine to reserve neuromuscular blocking agents.
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT02102542
|Anesthesiology Department Siriraj Hospital|
|Bangkoknoi, Bangkok, Thailand, 10700|